Contrast agent developer E-Z-EM has signed an agreement with pharmaceutical giant Eli Lilly for U.S. marketing of Lilly’s Glucagon for Injection product, a recombinant form of glucagon. Lilly will pay E-Z-EM a promotional fee based on sales of the
Contrast agent developer E-Z-EM has signed an agreement with pharmaceutical giant Eli Lilly for U.S. marketing of Lillys Glucagon for Injection product, a recombinant form of glucagon. Lilly will pay E-Z-EM a promotional fee based on sales of the injectable product, which is used in diagnostic procedures for the gastrointestinal system and for the treatment of severe hypoglycemia in diabetic patients. When used in gastrointestinal diagnostics, glucagon relaxes smooth muscles in the gastrointestinal tract, and may improve the quality of radiological images. The deal is part of E-Z-EMs strategy of forging healthcare alliances to bring key products to market, according to Howard Stern, chairman of the Wesbury, NY-based E-Z-EM. Lilly launched Glucagon in March.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.